Generic Pharma
Generics, biosimilars and specialty pharma companies focus on cost-competitive supply or niche formulation and complex / hospital-only medicines.
Strategic clarity in competitive and fast-moving markets
Identifying Growth and Value in Generic Pharma
The generic pharma markets are evolving rapidly. For generics, consolidation among buyers, intensified competition and continued price pressure are reshaping profitability. Both generic and specialty markets demand rigorous evaluation of where genuine value can be created.
We help investors and management teams assess opportunities with precision. Our experience spans commercial due diligence, transaction and licensing support, and portfolio strategy. We analyse market dynamics, competitor positioning, and product-level economics to determine where growth prospects are credible and where risks may be understated.
Our generic pharma leads
Our teams benchmark valuations against relevant deal activity, review R&D and pipeline sustainability, and assess regulatory and pricing environments across regions. This provides clients with a clear view of realistic market potential, informed by both scientific and commercial perspectives.
Beyond individual transactions, we support strategy development by examining market entry options, growth strategies, and partnership opportunities. By combining rigorous analysis with practical insight, we enable generics and specialty pharma companies — and their investors — to make sound strategic choices and capture long-term value.
News & Insights
